Single User License
INR 101895
Site License
INR 203790
Corporate User License
INR 305685

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Kyowa Hakko Kirin Co., Ltd.-Product Pipeline Review-2015

Kyowa Hakko Kirin Co., Ltd.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Kyowa Hakko Kirin Co., Ltd.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Kyowa Hakko Kirin Co., Ltd.-Product Pipeline Review-2015', provides an overview of the Kyowa Hakko Kirin Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kyowa Hakko Kirin Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Kyowa Hakko Kirin Co., Ltd. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Kyowa Hakko Kirin Co., Ltd.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Kyowa Hakko Kirin Co., Ltd.'s pipeline products

Reasons To Buy

Evaluate Kyowa Hakko Kirin Co., Ltd.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Kyowa Hakko Kirin Co., Ltd. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Kyowa Hakko Kirin Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Kyowa Hakko Kirin Co., Ltd. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kyowa Hakko Kirin Co., Ltd.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Kyowa Hakko Kirin Co., Ltd. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Kyowa Hakko Kirin Co., Ltd. Snapshot 8

Kyowa Hakko Kirin Co., Ltd. Overview 8

Key Information 8

Key Facts 8

Kyowa Hakko Kirin Co., Ltd.-Research and Development Overview 9

Key Therapeutic Areas 9

Kyowa Hakko Kirin Co., Ltd.-Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products-Monotherapy 14

Pipeline Products-Partnered Products 15

Partnered Products/Combination Treatment Modalities 16

Pipeline Products-Out-Licensed Products 17

Out-Licensed Products/Combination Treatment Modalities 18

Kyowa Hakko Kirin Co., Ltd.-Pipeline Products Glance 19

Kyowa Hakko Kirin Co., Ltd.-Late Stage Pipeline Products 19

Pre-Registration Products/Combination Treatment Modalities 19

Filing rejected/Withdrawn Products/Combination Treatment Modalities 20

Phase III Products/Combination Treatment Modalities 21

Kyowa Hakko Kirin Co., Ltd.-Clinical Stage Pipeline Products 22

Phase II Products/Combination Treatment Modalities 22

Phase I Products/Combination Treatment Modalities 23

Kyowa Hakko Kirin Co., Ltd.-Early Stage Pipeline Products 24

Preclinical Products/Combination Treatment Modalities 24

Discovery Products/Combination Treatment Modalities 25

Kyowa Hakko Kirin Co., Ltd.-Drug Profiles 26

KW-3357 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

tivozanib 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

benralizumab 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

brodalumab 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

darbepoetin alfa (recombinant) 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

granisetron ER 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

istradefylline 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

mogamulizumab 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

tivantinib 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

ASKP-1240 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

bardoxolone methyl 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

KHK-4577 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

KRN-23 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

romiplostim 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

BIW-8962 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

KHK-2823 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

KHK-2898 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

KHK-4083 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

KHK-6640 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

DsiRNA to Inhibit KRAS for Solid Tumor 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

DsiRNAs for Solid Tumor 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

K-685 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

K-756 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Ki-26894 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

KM-2812 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

KW-6356 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Z-3G1 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Bispecific Antibodies for Undisclosed Indication 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

K-777 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Small Molecules Targeting Protein-Protein Interactions for Undisclosed Indication 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Kyowa Hakko Kirin Co., Ltd.-Pipeline Analysis 71

Kyowa Hakko Kirin Co., Ltd.-Pipeline Products by Target 71

Kyowa Hakko Kirin Co., Ltd.-Pipeline Products by Route of Administration 74

Kyowa Hakko Kirin Co., Ltd.-Pipeline Products by Molecule Type 75

Kyowa Hakko Kirin Co., Ltd.-Pipeline Products by Mechanism of Action 76

Kyowa Hakko Kirin Co., Ltd.-Recent Pipeline Updates 79

Kyowa Hakko Kirin Co., Ltd.-Dormant Projects 100

Kyowa Hakko Kirin Co., Ltd.-Discontinued Pipeline Products 101

Discontinued Pipeline Product Profiles 101

AGS-003 101

AGS-004 101

darbepoetin alfa (recombinant) 101

KHK-2866 102

KHK-6188 102

KRN-330 102

KRX-0601 102

KW-2449 102

KW-2450 102

KW-2478 103

KW-7158 103

litronesib 103

mogamulizumab 103

pibrozelesin hydrobromide 103

tivantinib 104

tivozanib 104

Kyowa Hakko Kirin Co., Ltd.-Company Statement 105

Kyowa Hakko Kirin Co., Ltd.-Locations And Subsidiaries 106

Head Office 106

Other Locations & Subsidiaries 106

Appendix 110

Methodology 110

Coverage 110

Secondary Research 110

Primary Research 110

Expert Panel Validation 110

Contact Us 110

Disclaimer 111

List of Tables

Kyowa Hakko Kirin Co., Ltd., Key Information 8

Kyowa Hakko Kirin Co., Ltd., Key Facts 8

Kyowa Hakko Kirin Co., Ltd.-Pipeline by Indication, 2015 11

Kyowa Hakko Kirin Co., Ltd.-Pipeline by Stage of Development, 2015 13

Kyowa Hakko Kirin Co., Ltd.-Monotherapy Products in Pipeline, 2015 14

Kyowa Hakko Kirin Co., Ltd.-Partnered Products in Pipeline, 2015 15

Kyowa Hakko Kirin Co., Ltd.-Partnered Products/ Combination Treatment Modalities, 2015 16

Kyowa Hakko Kirin Co., Ltd.-Out-Licensed Products in Pipeline, 2015 17

Kyowa Hakko Kirin Co., Ltd.-Out-Licensed Products/ Combination Treatment Modalities, 2015 18

Kyowa Hakko Kirin Co., Ltd.-Pre-Registration, 2015 19

Kyowa Hakko Kirin Co., Ltd.-Filing rejected/Withdrawn, 2015 20

Kyowa Hakko Kirin Co., Ltd.-Phase III, 2015 21

Kyowa Hakko Kirin Co., Ltd.-Phase II, 2015 22

Kyowa Hakko Kirin Co., Ltd.-Phase I, 2015 23

Kyowa Hakko Kirin Co., Ltd.-Preclinical, 2015 24

Kyowa Hakko Kirin Co., Ltd.-Discovery, 2015 25

Kyowa Hakko Kirin Co., Ltd.-Pipeline by Target, 2015 72

Kyowa Hakko Kirin Co., Ltd.-Pipeline by Route of Administration, 2015 74

Kyowa Hakko Kirin Co., Ltd.-Pipeline by Molecule Type, 2015 75

Kyowa Hakko Kirin Co., Ltd.-Pipeline Products by Mechanism of Action, 2015 77

Kyowa Hakko Kirin Co., Ltd.-Recent Pipeline Updates, 2015 79

Kyowa Hakko Kirin Co., Ltd.-Dormant Developmental Projects,2015 100

Kyowa Hakko Kirin Co., Ltd.-Discontinued Pipeline Products, 2015 101

Kyowa Hakko Kirin Co., Ltd., Other Locations 106

Kyowa Hakko Kirin Co., Ltd., Subsidiaries 107

List of Figures

Kyowa Hakko Kirin Co., Ltd.-Pipeline by Top 10 Indication, 2015 10

Kyowa Hakko Kirin Co., Ltd.-Pipeline by Stage of Development, 2015 13

Kyowa Hakko Kirin Co., Ltd.-Monotherapy Products in Pipeline, 2015 14

Kyowa Hakko Kirin Co., Ltd.-Partnered Products in Pipeline, 2015 15

Kyowa Hakko Kirin Co., Ltd.-Out-Licensed Products in Pipeline, 2015 17

Kyowa Hakko Kirin Co., Ltd.-Pipeline by Top 10 Target, 2015 71

Kyowa Hakko Kirin Co., Ltd.-Pipeline by Top 10 Route of Administration, 2015 74

Kyowa Hakko Kirin Co., Ltd.-Pipeline by Top 10 Molecule Type, 2015 75

Kyowa Hakko Kirin Co., Ltd.-Pipeline Products by Top 10 Mechanism of Action, 2015 76

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Kyowa Hakko Kirin Co., Ltd.; Kyowa Hakko Kirin Co., Ltd. - Key Therapeutics; Kyowa Hakko Kirin Co., Ltd. - Pipeline Overview and Promising Molecules; Kyowa Hakko Kirin Co., Ltd. - News; Kyowa Hakko Kirin Co., Ltd. - Latest Updates; Kyowa Hakko Kirin Co., Ltd. - Pipeline; Kyowa Hakko Kirin Co., Ltd. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com